Q2 2012

13.08.2012 • News

Oxea Reports Robust Earnings and Strong Cash Flows

Oxea, a global supplier of Oxo Intermediates and Oxo Derivatives, today announced robust earnings for the second quarter of 2012, with net sales of €380 million getting close to prior year's level.

Top-Feature

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Photo
Oxea